Živný J H, Leahomschi S, Klener P, Živný J, Haluzík M, Cibula D
Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Czech Republic.
Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
Folia Biol (Praha). 2016;62(6):258-262. doi: 10.14712/fb2016062060258.
Osteopontin (OPN) is a novel biomarker of various cancers including ovarian carcinoma. OPN is a promising adjunct to a major biomarker of ovarian cancer, CA125, in diagnosis, differential diagnosis and prognosis. The aim of our study was to measure the plasma level of OPN and CA125 in patients with borderline ovarian tumours (BOTs), serous ovarian carcinoma, and controls to determine its potential role in the differential diagnosis between serous ovarian carcinoma and BOT. The plasma samples of 66 women were analysed using Luminex technology, designed to simultaneously measure multiple specific protein targets. The mean OPN plasma level for the control group was 23.3 ng/ml; for BOT 26.3 ng/ml; and for patients with serous ovarian carcinoma 59.5 ng/ml. Specifically, there was a significant difference between the OPN levels in patients with ovarian carcinoma and BOT (P < 0.001) as well as controls (P < 0.001). There was no difference between the mean levels of OPN in patients with BOT and the control group (P = 0.286). Using the receiver operating characteristic (ROC), we determined the utility of OPN and CA125 to differentiate between BOT and serous ovarian carcinoma. The area under the ROC curve (AUC) for OPN was 0.793 (95% confidence interval (CI) 0.669-0.917, P < 0.001) and for CA125 0.766 (95% CI 0.626-0.907, P = 0.002). Based on our data, we suggest that OPN can be used as a possible differential diagnostic biomarker to distinguish between malignant serous ovarian carcinoma and BOT.
骨桥蛋白（OPN）是包括卵巢癌在内的多种癌症的新型生物标志物。OPN有望作为卵巢癌主要生物标志物CA125的辅助指标，用于诊断、鉴别诊断和预后评估。我们研究的目的是测量卵巢交界性肿瘤（BOTs）、浆液性卵巢癌患者及对照组血浆中OPN和CA125的水平，以确定其在浆液性卵巢癌与BOT鉴别诊断中的潜在作用。采用Luminex技术分析了66名女性的血浆样本，该技术可同时测量多个特定蛋白质靶点。对照组血浆OPN平均水平为23.3 ng/ml；BOT组为26.3 ng/ml；浆液性卵巢癌患者为59.5 ng/ml。具体而言，卵巢癌患者与BOT患者以及对照组之间的OPN水平存在显著差异（P < 0.001）。BOT患者与对照组的OPN平均水平无差异（P = 0.286）。利用受试者工作特征曲线（ROC），我们确定了OPN和CA125在鉴别BOT与浆液性卵巢癌方面的效用。OPN的ROC曲线下面积（AUC）为0.793（95%置信区间（CI）0.669 - 0.917，P < 0.001），CA125的AUC为0.766（95%CI 0.626 - 0.907，P = 0.002）。基于我们的数据，我们建议OPN可作为鉴别恶性浆液性卵巢癌与BOT的一种可能的鉴别诊断生物标志物。
